The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Expediting treatment decision making in NSCLC with liquid biopsies
Luis Raez, MD, Memorial Cancer Institute, Pembroke Pines, FL, provides an overview of findings from a study utilizing liquid and tissue biopsies in patients with non-small cell lung cancer (NSCLC). Simultaneous use of liquid and tissue next-generation sequencing (NGS) techniques enabled the decision-making process to be done in approximately eight days, highlighting the benefits of liquid biopsies. Dr Raez subsequently suggests liquid biopsies to be used first over tissue biopsies. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
